PMID- 25396763
OWN - NLM
STAT- MEDLINE
DCOM- 20151022
LR  - 20150129
IS  - 1473-5733 (Electronic)
IS  - 0957-5235 (Linking)
VI  - 26
IP  - 2
DP  - 2015 Mar
TI  - Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis 
      inhibitor on the risk of diabetic macrovascular disease.
PG  - 185-90
LID - 10.1097/MBC.0000000000000216 [doi]
AB  - Hypofibrinolysis is commonly found in patients with diabetes mellitus and is 
      associated with the increased risk for many diabetic complications. An important 
      inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), 
      participates in hypofibrinolysis in diabetes mellitus and may be involved in 
      diabetic macrovascular disease. The present study was designed to determine 
      whether TAFI polymorphisms (505G/A and 1040C/T) and TAFI levels are correlated 
      with the development of type 2 diabetes mellitus (T2DM) and macrovascular 
      diseases (MVDs). A total of 249 clinical samples were collected, including 102 
      healthy individuals (H group), 44 T2DM patients without MVD (T group) and 103 
      T2DM patients with MVD (M group). The 505G/A polymorphism was equally represented 
      in the three groups. In contrast, analysis of the 1040C/T polymorphism revealed a 
      statistically lower percentage of the T allele in the M group than in the H group 
      (P = 0.014). This difference was due to decreased T/T homozygotes in the M groups 
      compared with the H group (P = 0.029). The antigen TAFI level was 31.72 +/- 13.64% 
      in the H group, 62.56 +/- 18.77% in the T group (P < 0.05, compared with the H 
      group) and 63.70 +/- 15.76% in the M group (P < 0.05, compared with the H group). 
      As high plasma TAFI level is associated with the increasing risk of T2DM, it may 
      thus serve as a potential marker for the diagnosis of T2DM.
FAU - Zheng, Chenghong
AU  - Zheng C
AD  - aThe First Hospital of Wuhan bTongji School of Pharmacy, Huazhong University of 
      Science and Technology, Wuhan, Hubei, P. R. China cDepartments of Pathology, 
      Neuroscience and Neurology, Case Western Reserve University, Cleveland, Ohio, USA 
      dCentre for Biomedicine Research, Wuhan Institute of Biotechnology, Wuhan, Hubei, 
      P. R. China.
FAU - Li, Xiaochao
AU  - Li X
FAU - Kong, Caixia
AU  - Kong C
FAU - Ke, Shuhong
AU  - Ke S
FAU - Peng, Cong
AU  - Peng C
FAU - Cui, Tianpen
AU  - Cui T
FAU - Gao, Mingsong
AU  - Gao M
FAU - Zhou, Yang
AU  - Zhou Y
FAU - Guo, Wei
AU  - Guo W
FAU - Huang, Lianqi
AU  - Huang L
FAU - Petersen, Robert B
AU  - Petersen RB
FAU - Huang, Kun
AU  - Huang K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - EC 3.4.17.20 (Carboxypeptidase B2)
SB  - IM
MH  - Carboxypeptidase B2/*genetics
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/complications/*genetics
MH  - Diabetic Angiopathies/blood/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
EDAT- 2014/11/15 06:00
MHDA- 2015/10/23 06:00
CRDT- 2014/11/15 06:00
PHST- 2014/11/15 06:00 [entrez]
PHST- 2014/11/15 06:00 [pubmed]
PHST- 2015/10/23 06:00 [medline]
AID - 10.1097/MBC.0000000000000216 [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2015 Mar;26(2):185-90. doi: 
      10.1097/MBC.0000000000000216.